Renaissance Technologies’s Jasper Therapeutics JSPR Stock Holding History

Renaissance Technologies’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$100K	Buy	237,900 +60,400	+34%	+$45.2K	﹤0.01%	2978
2026 Q1	$156K	Sell	177,500 -49,683	-22%	-$69K	﹤0.01%	2958
2025 Q4	$416K	Buy	227,183 +18,683	+9%	+$37.5K	﹤0.01%	2643
2025 Q3	$496K	Buy	208,500 +198,100	+1,905%	+$601K	﹤0.01%	2794
2025 Q2	$57.7K	Buy	+10,400	New	+$51.2K	﹤0.01%	3373
2024 Q1	–	Sell	-51,432	Closed	-$406K	–	3898
2023 Q4	$406K	Buy	51,432 +20,411	+66%	+$137K	﹤0.01%	2868
2023 Q3	$217K	Buy	31,021 +25,211	+434%	+$308K	﹤0.01%	3063
2023 Q2	$80K	Sell	5,810 -5,210	-47%	-$77.4K	﹤0.01%	3519
2023 Q1	$199K	Buy	11,020 +4,480	+69%	+$82.8K	﹤0.01%	3286
2022 Q4	$32K	Buy	6,540 +3,680	+129%	+$24.6K	﹤0.01%	3876
2022 Q3	$23K	Buy	+2,860	New	+$52.3K	﹤0.01%	3880
2022 Q2	–	Sell	-1,087	Closed	-$39K	–	4412
2022 Q1	$39K	Buy	+1,087	New	+$49K	﹤0.01%	3940

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies's JSPR Position: Q2 2026 in Review

Renaissance Technologies increased its Jasper Therapeutics (JSPR) stake by 34% in Q2 2026, buying an estimated $45.2K and bringing the position to 237,900 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #2978.

Renaissance Technologies first reported a position in JSPR in Q1 2022 and has held it in 12 quarters since. The position peaked at $496K in Q3 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

Renaissance Technologies held 237,900 shares of Jasper Therapeutics worth $100K as of Q2 2026.
Renaissance Technologies bought 60,400 Jasper Therapeutics shares in Q2 2026, an estimated $45.2K.
Jasper Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2978 holding.
Renaissance Technologies first reported a position in Jasper Therapeutics in Q1 2022 and has held it in 12 quarters since.
Renaissance Technologies's Jasper Therapeutics position peaked at $496K in Q3 2025.
45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.